Table 1.

First generation of HIV pre-exposure prophylaxis trials

Sponsor	Place, expected start date	Population	Exposure	Sample size	Study aim	Duration (months)	Status
NIH/FHI	Cambodia, 2004	Women	Vaginal	960	Safety and efficacy	12	Stopped before start
FHI	Ghana, 2005	Women	Vaginal	400	Safety	12	Completed
FHI	Nigeria, 2005	Women	Vaginal	400	Safety	12	Stopped after enrolling 120
FHI	Cameroon, 2005	Women	Vaginal	400	Safety	12	Stopped after enrolling 400
FHI	Malawi, 2005	Heterosexual men	Penile	400	Safety	12	Stopped before start
CDC	Thailand, 2005	PWID	Parenteral	1200	Safety and efficacy	12	Completed
CDC	Botswana, 2005	Heterosexual men and women	Vaginal/penile	1600	Safety and efficacy	18	Completed
CDC	San Francisco, Atlanta, Boston, USA; 2005	MSM	Penile/rectal	400	Safety	15	Completed
NIH	Peru/Ecuador, 2007	MSM	Penile/rectal	1400	Safety and efficacy	18	Completed

NIH, National Institutes of Health; FHI360, Family Health International; CDC, US Center for Disease Control, PWID, people who inject drugs; MSM, men who have sex with men.